Peer-Reviewed Publication
JCI Insight2026;11(12)June 22, 2026Journal Article
Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma.
Sridevi Rajeeve1, Matt Wilkes2, Nicole Zahradka2, Lewis Tomalin3, Mujahid Quidwai4, Darren Pan5, Nicholas J Calafat2, Martin Cusack2, Adolfo Aleman6,7, Kseniya Serebryakova6,7, Katerina Kappes6,7, Hayley Jackson6,7, Sarita Agte8, Santiago Thibaud6,7, Larysa Sanchez6,7, Shambavi Richard6,7, Joshua Richter6,7, Cesar Rodriguez6,7, Hearn Jay Cho6,7, Ajai Chari5, Sundar Jagannath6,7, Alessandro Laganà4,7,9, Adriana C Rossi6,7, Samir Parekh6,7
1Myeloma & Cellular Therapy Services, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
2Current Health Inc., Boston, Massachusetts, USA.
3Department of Population Health Science and Policy and.
4Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
5University of California San Francisco, San Francisco, California, USA.
6Department of Medicine, Hematology and Medical Oncology and.
7Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
8Dorset County Hospital, NHS Foundation Trust, Dorchester, United Kingdom.
9Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Abstract
BACKGROUNDChimeric antigen receptor T-cell (CAR-T) therapies have revolutionized treatment for relapsed/refractory multiple myeloma (RRMM). However, cytokine release syndrome (CRS), a common and potentially severe complication, requires inpatient monitoring, limiting access and increasing costs. Wearable devices could support outpatient CAR-T delivery, but feasibility for CRS detection versus stan…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans